GlassScriptPhysician profile
William N Landry
NPI 1821064106
$4,547.07
in general payments reported to CMS, 2019-2025
37 companies · $937 in 2025
The $937 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $583 · 2021: $640 · 2022: $827 · 2023: $654 · 2024: $443 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,393.25 | 2019-2023 | |
| Astellas Pharma US INC | $653.01 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $589.31 | 2022-2025 | |
| Therapeuticsmd, INC. | $285.80 | 2020-2022 | |
| Evofem Biosciences, INC. | $168.11 | 2021-2025 | Phexxi, Solosec, Phexx |
| Smith+Nephew, INC. | $138.19 | 2025 | Tc-100, Pico 14 |
| Avanos Medical | $113.62 | 2019 | |
| Lilly USA, LLC | $99.10 | 2019 | |
| Ascend Therapeutics US, LLC | $95.11 | 2022-2023 | |
| Scynexis, INC. | $90.69 | 2022 | |
| Hologic Sales and Service, LLC | $90.46 | 2021-2025 | Aptima |
| Avion Pharmaceuticals | $81.05 | 2021-2023 | Balcoltra |
| Millicent US INC | $76.14 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $63.79 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $54.58 | 2024-2025 | Myfembree |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofire Diagnostics, LLC | $47.92 | 2019 | |
| Mission Pharmacal Company | $45.20 | 2020-2021 | |
| Biom'Up France Sas | $43.45 | 2021 | |
| Agile Therapeutics, INC. | $39.25 | 2021-2022 | |
| Organon LLC | $35.92 | 2022-2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $30.78 | 2020-2021 | |
| Coloplast Corp | $29.86 | 2019 | |
| Mylan Pharmaceuticals INC. | $28.15 | 2021 | |
| Urovant Sciences INC | $28.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.98 | 2020-2023 | |
| Novo Nordisk INC | $21.03 | 2022 | |
| Medical Device Business Services, INC. | $19.86 | 2024 | N/A |
| Pacira Pharmaceuticals Incorporated | $19.67 | 2024 | Exparel |
| Sage Therapeutics, LLC | $18.11 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $17.92 | 2025 | Slynd |
| Currax Pharmaceuticals LLC | $17.23 | 2025 | Contrave, Onzetra Xsail |
| Roche Diagnostics Corporation | $16.37 | 2019 | |
| Lupin INC. | $16.24 | 2020 | |
| Aspira Women'S Health INC | $15.65 | 2022 | |
| Vertical Pharmaceuticals, LLC | $13.50 | 2019 | |
| Minerva Surgical, INC | $13.37 | 2019 | |
| Allergan, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Landry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.